Section Arrow
XBIT.NASDAQ
- XBiotech
Quotes are at least 15-min delayed:2026/07/15 19:00 EDT
After Hours
Last
 2.29
0 (0.00%)
Bid
2.29
Ask
2.31
High 2.29 
Low 2.29 
Volume 10 
Regular Hours (Closed)
Last
 2.29
0 (0.00%)
Day High 
2.31 
Prev. Close
2.29 
1-M High
2.4352 
Volume 
21.24K 
Bid
2.29
Ask
2.31
Day Low
2.28 
Open
2.31 
1-M Low
2.275 
Market Cap 
69.82M 
Currency 美元 
P/E -- 
%Yield 107.86 
10-SMA 2.33 
20-SMA 2.33 
50-SMA 2.39 
52-W High 3.61 
52-W Low 2.09 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.31/--
Enterprise Value
69.82M
Balance Sheet
Book Value Per Share
4.43
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.06
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
VIVSVivoSim Lab Inc0.8529+0.0181+2.17%0.47PE
After Hours 0.8103 -0.0426 -4.99%
LIMNLiminatus Pharma Inc0.1145+0.011+10.63%-- 
After Hours 0.1232 +0.0087 +7.60%
IOVAIovance Biotherapeutics4.74+0.81+20.61%-- 
After Hours 4.71 -0.03 -0.63%
KAPAKairos Pharma Ltd.0.318-0.022-6.47%-- 
After Hours 0.42 +0.102 +32.08%
PHIOPhio Pharmaceuticals Corp0.8901-0.1399-13.58%-- 
After Hours 0.93 +0.0399 +4.48%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.